Company news
Ocular Therapeutix, Inc. news in 2023
Ocular Therapeutix, Inc.'s news releases, calls and decks from 2023, newest first.
Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
December 17, 2023
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
December 12, 2023
Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
December 12, 2023
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
November 7, 2023
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
November 6, 2023
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
October 31, 2023
Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results
October 23, 2023
Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
October 2, 2023
Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
August 8, 2023
Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
August 6, 2023
Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results
July 23, 2023
Ocular Therapeutix™ Announces Appointment of New Board Member
July 11, 2023
Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
June 9, 2023
Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy
June 6, 2023
Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
June 4, 2023
Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
May 31, 2023
Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference
May 7, 2023
Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update
May 7, 2023
Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 27, 2023
Ocular Therapeutix™ To Report First Quarter 2023 Financial Results
April 23, 2023
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 13, 2023
Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update
March 5, 2023
Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference
February 27, 2023
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results
February 20, 2023
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
February 10, 2023
Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones
January 5, 2023
Calls in 2023
- Ocular Therapeutix (NASDAQ:OCUL) Q3 2023 Earnings Call
Nov 7, 2023
Transcript - Ocular Therapeutix (NASDAQ:OCUL) Q2 2023 Earnings Call
Aug 7, 2023
Transcript - Ocular Therapeutix (NASDAQ:OCUL) Q1 2023 Earnings Call
May 8, 2023
Transcript - Ocular Therapeutix (NASDAQ:OCUL) Q4 2022 Earnings Call
Mar 7, 2023
Transcript
Decks in 2023
- EURETINA Innovation Spotlight 2023
Conference · 18 slides · Oct 4, 2023
- Technical Presentation (June 2023)
Technical · 6 slides · Jun 12, 2023